1 · Estrogen departs — from fluctuation to a durable low
Once you've gone 12 consecutive months without a period, you enter postmenopause: a stable, durable low-estrogen state that lasts roughly a third of the rest of your life.The key distinction: perimenopause is about fluctuation; postmenopause is about stabilizing at a low level. Some symptoms fade naturally (most hot flashes), but others do not self-resolve and instead progress with the low-estrogen state (bone loss, GSM). Before menopause, estrogen is a system-wide protective hormone — not just reproductive.
2 · Bone — the acceleration window is right around menopause
The single most important sentence on postmenopausal bone: bone loss is not 'aging' that starts at 70 — it bursts in the years around the final menstrual period (FMP).Mechanism: with normal estrogen, osteoclasts are held down (↑OPG + ↓); with estrogen withdrawal → RANKL↑ → osteoclasts off the leash, resorption exceeds formation. The SWAN cohort (Greendale 2012) quantified this 'transmenopause' window: lumbar and femoral-neck density fall ~2% per year, markedly faster than before or after. Fracture consequences appear after 65 — but the bone capital is rapidly drained in that window around 50. The prevention window comes first, the consequences later.
3 · System fan-out — the four things estrogen was protecting
Once estrogen departs, the systems it protected (bone, vessels, urogenital tissue and metabolism) reset one by one.Bone: osteoclasts unleashed → accelerated loss (dive to osteoporosis)Vessels: endothelial function↓, worsening lipid profile → cardiovascular risk rises (the transition is an acceleration point, El Khoudary 2020)Urogenital (GSM): thinning vaginal / urethral epithelium — it persists and progresses without treatment, harder the longer you wait. NAMS 2020 calls low-dose vaginal estrogen an effective treatment (a judgement, not an efficacy rate), and it is not bound by systemic 's timing window. Breast-cancer history is the exception: that statement says the data are insufficient to confirm safety, so the decision belongs with the oncologistMetabolic / body composition: fat redistributes from subcutaneous (pear) to visceral (apple) → insulin resistance↑ The stance: risk does rise, but each has clear monitoring metrics and modifiable levers — not decline, but a life stage you can actively manage.
4 · The MHT timing window — not 'whether' but 'when'
timing mainly shifts the risk-benefit balance rather than long-term mortality, so it should start early in menopause and before 60, weighed individually with a clinician.Menopausal hormone therapy () is the most misunderstood topic in menopause medicine. The 2002 WHI trial was misread (participants averaged 63, many a decade past menopause), casting a 20-year shadow.
The timing hypothesis (Manson 2017, WHI 18-year follow-up re-stratified by age): start with the paper's own conclusion — over 18 years of cumulative follow-up, MHT was not associated with all-cause mortality (0.99, 95% 0.94-1.03), nor with cardiovascular or cancer mortality. Split by starting age, women who began at 50-59 had lower all-cause mortality during the years on treatment (HR 0.69, 95% CI 0.51-0.94), but across the full 18 years the difference was no longer significant (HR 0.89, 95% CI 0.79-1.01). So the timing window mainly shifts the risk-benefit balance, not long-term mortality: MHT should start in the 'early menopause + before 60' window, but that is not a reason to take it for longevity. Breast-cancer risk should be read in absolute numbers (5 years of E+P adds ~4-5 cases per 1,000, an absolute increment of ~0.4-0.5%), not scary .
MHT is not a 'should I or shouldn't I' yes/no — it is an individualized weighing under your age, years since menopause, symptoms, and risk profile, decided together with your clinician.